Baker IDI Heart & Diabetes Institute Holdings Ltd.;Universitatsklinikum Freiburg
发明人:
Zirlik, Andreas,Wolf, Dennis,Peter, Karlheinz
申请号：
AU2011317807
公开号：
AU2011317807A1
申请日:
2011.08.17
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
